GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

edifoligide   Click here for help

GtoPdb Ligand ID: 13633

Synonyms: CGT-003 | CGT003 | E2F Duplex Decoy
Compound class: Nucleic acid
Comment: Edifoligide is an oligonucleotide decoy that binds to and inhibits activity of E2F transcription factors that regulate expression of genes controlling smooth muscle cell proliferation. This is proposed as a mechanism to reduce the progressive neointimal hyperplasia that contributes to vein graft failure following coronary artery bypass graft (CABG) surgery [2-4].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Edifoligide was progressed to phase 3 clinical evaluation, but it failed to show efficacy in preventing vein graft failure/stenosis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00042081 Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures Phase 3 Interventional Anesiva, Inc. Data from this study showed that edifoligide was not effective in preventing vein graft failure within 12 to 18 months after CABG. 1